Astragaloside IV alleviates heart failure by regulating SUMO-specific protease 1

Shi-peng Dai,N. Xue,X. Bian,Ya Li,Jiancai Yu,Xiaozhi Liu,Juan Liu

DOI: https://doi.org/10.3892/etm.2021.10510

IF: 2.7

2021-07-28

Experimental and Therapeutic Medicine

Abstract:The present study investigated whether the protective effect and mechanism of astragaloside IV (AS-IV) on heart failure (HF) involves small ubiquitin-like modifier (SUMO)-specific protease 1 (Senp1). Mouse HF was established by aortic constriction, inducing pressure overload. The model was confirmed by echocardiography 6 weeks after surgery. Mice were randomly divided into control, HF, HF+AS-IV, and AS-IV groups. Ventricular function was examined by echocardiography. Morphological changes of myocardial tissues were examined by H&E staining. The protein levels of the apoptosis-related proteins, cleaved caspase-3, caspase-3, Bcl2, Bax, and SUMO-Senp1 were determined by Western blotting. H2O2 in isolated mitochondria and cells was determined by Amplex Red. A reactive oxygen species (ROS) detection kit determined ROS levels in isolated mitochondria and HL-1 cells. JC-1 reagent measured mitochondrial membrane potential (ΔΨm). Apoptosis of HL-1 cells was examined by terminal deoxynucleotidyl transferase dUTP nick end labeling. Compared with the control group, the heart weight and heart mass/body weight ratio increased in the HF group (P<0.05). Furthermore, the ejection fraction and left ventricular shortening fraction decreased (P<0.05), while the left ventricular end-diastolic diameter (LVID;d) and end-systolic diameter (LVID;s) increased (P<0.05). Finally, mitochondrial ROS and H2O2 increased (P<0.05), while the ΔΨm decreased (P<0.05). However, AS-IV improved the cardiac function of HF mice, decreased the level of ROS and H2O2 in the myocardium, suppressed the decrease in ΔΨm, and decreased the apoptosis of myocardial cells (P<0.05). AS-IV also decreased the Senp1-overexpression. Furthermore, in HL-1 cells, Senp1-overexpression significantly inhibited the protective effects of AS-IV. AS-IV decreased oxidative stress in cardiomyocytes, decreased mitochondrial damage, inhibited ventricular remodeling, and ultimately improved cardiac function by inhibiting HF-induced Senp1-overexpression. This mechanism provides a novel theoretical basis and clinical treatment for HF.

Medicine

What problem does this paper attempt to address?

The problem this paper attempts to address is the exploration of the protective effects and mechanisms of Astragaloside IV (AS-IV) in heart failure (HF), particularly whether it achieves this protection by regulating SUMO-specific protease 1 (Senp1). The study simulates heart failure by establishing a mouse model of aortic constriction and verifies the effects of AS-IV on cardiac function and oxidative stress both in vivo and in vitro. Additionally, by modulating the expression of Senp1 in the HL-1 cell line, the study further investigates whether the cardioprotective effects of AS-IV are related to Senp1. The research results provide a new theoretical basis and clinical reference for SUMOylation-based HF therapy.